Misonix, Inc. Unveils New SonicOne® O.R. App To Highlight Advantages of Ultrasonic Wound Debridement in Acute and Chronic Wounds

Jul 23, 2015, 08:00 ET from Misonix, Inc.

FARMINGDALE, N.Y., July 23, 2015 /PRNewswire/ -- Misonix, Inc. (NASDAQ: MSON), an international surgical device company that designs, manufactures and markets innovative therapeutic ultrasonic products for spine surgery, skull based surgery, neurosurgery, wound debridement, cosmetic surgery, laparoscopic surgery and other surgical applications, announced the launch of its SonicOne O.R. app for iPad mobile devices.

The new iPad app was designed to educate users on the extensive benefits of ultrasonic wound debridement using the SonicOne technology. Users can explore the science behind the SonicOne O.R. with 3D animation of the innovative ultrasound technology, witness the macro and microscopic interaction of ultrasound in a wound environment, and observe the surgical technique used for debriding a wound in the 3D wound animation. The app also contains extensive material on SonicOne O.R.'s clinical and economic benefits, key publications and endorsements from distinguished surgeons who have made SonicOne a standard of care in their practice.

Commenting on the new app, Dr. David Pougatsch, attending & teaching faculty member in the department of Surgery at Cedars-Sinai Medical Center in Los Angeles, CA and Director of the Sherman Oaks Hospital Amputation Prevention Center said, "I've been very impressed with the SonicOne O.R. over the past two years and it has become a standard of care in our treatment protocols for some of the most challenging cases in preventing limb amputations.  This new digital content, now available on the iTunes store, allows the clinicians to gain a more comprehensive understanding of how this advanced technology works and will become a great educational tool for new surgeons. Additionally, we will now have a fantastic mobile tool for showing our patients exactly what this therapy and treatment is doing.  This app does a wonderful job in distilling some very technical microbiologic information regarding the SonicOne O.R. mechanism of action into an easy to understand animation for patients and non-clinical viewers."

"This new iPad app continues our commitment to develop new tools to better communicate with our rapidly expanding global customer base and international stakeholders," said Michael A. McManus, Jr., President and Chief Executive Officer of Misonix. "We have continued to expand our digital platform through regular updates to include new information, surgical videos, product offerings and functionality, which will be available in the Apple iTunes store.  Surgeons around the world now have direct access to the most up-to-date SonicOne technical information and they also have the ability to schedule a surgical evaluation directly through the app."

About Misonix

Misonix, Inc. designs, develops, manufactures and markets therapeutic ultrasonic medical devices. Misonix's therapeutic ultrasonic platform is the basis for several innovative medical technologies. Addressing a combined market estimated to be in excess of $1.5 billion annually; Misonix's proprietary ultrasonic medical devices are used for wound debridement, cosmetic surgery, neurosurgery, laparoscopic surgery, and other surgical and medical applications. Additional information is available on the Company's Web site at www.misonix.com.

Safe Harbor Statement

With the exception of historical information contained in this press release, content herein may contain "forward looking statements" that are made pursuant to the Safe Harbor Provisions of the Private Securities Litigation Reform Act of 1995. These statements are based on management's current expectations and are subject to uncertainty and changes in circumstances. Investors are cautioned that forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from the statements made. These factors include general economic conditions, delays and risks associated with the performance of contracts, risks associated with international sales and currency fluctuations, uncertainties as a result of research and development, acceptable results from clinical studies, including publication of results and patient/procedure data with varying levels of statistical relevancy, risks involved in introducing and marketing new products, potential acquisitions, consumer and industry acceptance, litigation and/or court proceedings, including the timing and monetary requirements of such activities, the timing of finding strategic partners and implementing such relationships, regulatory risks including approval of pending and/or contemplated 510(k) filings, the ability to achieve and maintain profitability in the Company's business lines, and other factors discussed in the Company's Annual Report on Form 10-K, subsequent Quarterly Reports on Form 10-Q and Current Reports on Form 8-K. The Company disclaims any obligation to update its forward-looking relationships.

Misonix Contact:

Investor Contact:

Richard Zaremba

Joe Diaz


Lytham Partners





SOURCE Misonix, Inc.